Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod|
Rintatolimod is a dsRNA polymer and a restricted Toll-Like Receptor 3 agonist that lacks activation of other primary cellular inducers of innate immunity, and has broad antiviral and immunomodulatory properties (PMID: 27045557).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Celecoxib||Celebra||Celebra (celecoxib) is a COX-2 inhibitor FDA approved as an anti-inflammatory agent and for colorectal polyp reduction (FDA.gov) and also promotes apoptosis of tumor cells (PMID: 17909047).|
|Interferon alpha-2b||Intron A||Alfatronol|Alfatronol|interferon alpha-2b|Sch 30500|
|Pembrolizumab||Keytruda||MK-3475||Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 67||Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, PD-L1 expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, cervical cancer, and triple-negative breast cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib in RCC, with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, and in combination with platinum and fluoropyrimidine-based chemotherapy for patients with esophageal or gastroesophageal carcinoma (FDA.gov).|
|Rintatolimod||Ampligen|Atvogen|Poly(I).Poly(c12,U)||Rintatolimod (Ampligen) is a synthetic dsRNA molecule that activates TLR3 and other interferon-induced proteins, which may result in increased anti-tumor immune response (PMID: 27045557, PMID: 19200817).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03599453||Phase I||Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod||Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer||Active, not recruiting||USA||0|